Now Is The Time! Rule Changes To Open Up China To Foreign New Drugs?
Executive Summary
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to bolster multinationals’ interest and activity in China, and to quicken the pace of launches to potentially overcome the country’s “drug lag”.
You may also be interested in...
Interview: Beigene Bursts Onto World IO Scene With Celgene Onboard (Part 2)
Howard Liang comes from an investment background with years of experience honed being the former managing director and head of biotech equity research at Leerink Partners. He became Beigene's CFO and Chief Strategy Officer in 2015 as the biotech prepared for its initial public offering (IPO) on Nasdaq, and has since seen the Beijing-based firm leap onto the world stage with differentiated immuno-oncology and BTK inhibitor assets.
As Trump Meets Xi, Executives Face Changing Dynamics In China
China is aggressively driving up life sciences innovations, leading the charge in technologies including gene editing and genome testing, prompting executives to take a fresh approach.
Big Pharma CEOs Descend On China: What’s The Likely Agenda?
In a major show of force, four global pharma CEOs are heading to China to participate in high-level open and closed-door discussions that are expected to include a range of policy and regulatory reform topics. Tapping into China’s push to improve health and develop an innovation-driven economy may provide new openings for their voices to be heard.